Martin Novák

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt et al. · Circulation · 2022 · 148 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial

Johanne Silvain, Benoît Lattuca, Farzin Beygui et al. · The Lancet · 2020 · 130 citations

Medicine, Cardiology, Pharmacology +14

<scp>CD</scp>38‐negative relapse in multiple myeloma after daratumumab‐based chemotherapy

Jiří Minařík, Martin Novák, Patrik Flódr et al. · European Journal Of Haematology · 2017 · 24 citations

Medicine, Hematology, Oncology +16

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients

Václava Polívková, Peter Rohoň, Hana Klamová et al. · PLoS ONE · 2016 · 22 citations · Full text

Life Sciences, Hematology, Immunology +14

Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers

Martin Novák, Vít Procházka, Peter Turcsányi et al. · Acta Haematologica · 2015 · 19 citations

Life Sciences, Hematology, Immunology +16